Week in Review: Breaking Down the Barriers to Patient Health

Week in Review: Breaking Down the Barriers to Patient Health

08.22.14 | By

This week, we addressed some of the barriers that patients face when it comes to their health and how the biopharmaceutical industry helps individuals get the treatments they need.

The growing concern for the obstacles patients face when getting needed medicines under the Affordable Care Act’s (ACA) Health Insurance Exchanges was highlighted in the Associated Press. In a letter sent to Health and Human Services (HHS) Secretary Sylvia Mathews, 333 patient groups voiced their concern regarding the high price of premiums and the discrimination patients with chronic conditions are facing. With open enrollment fast approaching in November, it is important that we work together to not only address these barriers, but also help patients choose the insurance plan that best fits their needs. As open enrollment approaches, we will be discussing health insurance in more detail, and encourage you to check back after Labor Day for more information.

Information is power, and providing patients with accurate, relevant information is a priority. Unfortunately, misinformation about health care is still prevalent and negatively affects health-related decisions and outcomes. According to findings from PhRMA’s Second Annual National Health Survey, one in four Americans consider vaccines to be a cause of autism in young children. With National Immunization Awareness Month coming to an end and the school year beginning, the importance of vaccinations for both children and adults remains top-of-mind. Keeping up-to-date on recommended immunizations is essential to your health and the health of those around you.

News travels fast. Make sure you are sharing accurate and credible information. Follow us on Facebook and Twitter for daily updates from around the industry and share the information with others to help spread the word about the importance of innovative medicines to help patients. 


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context